Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Maine Attorney General Aaron Frey announced a settlement agreement Tuesday with Sanofi-Aventis U.S. following scrutiny over the company’s pricing of insulin products. Sign up for our Newsletters Under ...

South Africa's Competition Commission is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Sanofi’s management has highlighted fitusiran, a potential competitor to Roche’s haemophilia A drug Hemlibra, as one of the most important drugs in its pipeline.

Detailed trial results could help Sanofi and Teva Pharmaceuticals make a case that a drug they’ve been developing will be competitive with rival treatments from Merck & Co. and Roche. The data, ...

I have tested multiple AI models, particularly image models and they each have something unique to offer. AI image generation has come a long way in a few short years. The first version of ...

Opella is well-known in France for manufacturing the painkiller Doliprane. Image credit: Shutterstock / Leitenberger Photography. Sanofi’s sale of its $17bn consumer health business Opella just ...

Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...

Regeneron and Sanofi have collaborated on Dupixent since 2007. Credit: The Washington Post via Getty Images. Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another ...